Literature DB >> 12707387

Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease.

Riccardo Magistroni1, Ning He, Kairong Wang, Robin Andrew, Ann Johnson, Patricia Gabow, Elizabeth Dicks, Patrick Parfrey, Roser Torra, Jose L San-Millan, Eliecer Coto, Marjan Van Dijk, Martijn Breuning, Dorien Peters, Nadja Bogdanova, Giulia Ligabue, Alberto Albertazzi, Nick Hateboer, Kyproula Demetriou, Alkis Pierides, Constantinos Deltas, Peter St George-Hyslop, David Ravine, York Pei.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a common Mendelian disorder that affects approximately 1 in 1000 live births. Mutations of two genes, PKD1 and PKD2, account for the disease in approximately 80 to 85% and 10 to 15% of the cases, respectively. Significant interfamilial and intrafamilial renal disease variability in ADPKD has been well documented. Locus heterogeneity is a major determinant for interfamilial disease variability (i.e., patients from PKD1-linked families have a significantly earlier onset of ESRD compared with patients from PKD2-linked families). More recently, two studies have suggested that allelic heterogeneity might influence renal disease severity. The current study examined the genotype-renal function correlation in 461 affected individuals from 71 ADPKD families with known PKD2 mutations. Fifty different mutations were identified in these families, spanning between exon 1 and 14 of PKD2. Most (94%) of these mutations were predicted to be inactivating. The renal outcomes of these patients, including the age of onset of end-stage renal disease (ESRD) and chronic renal failure (CRF; defined as creatinine clearance < or = 50 ml/min, calculated using the Cockroft and Gault formula), were analyzed. Of all the affected individuals clinically assessed, 117 (25.4%) had ESRD, 47 (10.2%) died without ESRD, 65 (14.0%) had CRF, and 232 (50.3%) had neither CRF nor ESRD at the last follow-up. Female patients, compared with male patients, had a later mean age of onset of ESRD (76.0 [95% CI, 73.8 to 78.1] versus 68.1 [95% CI, 66.0 to 70.2] yr) and CRF (72.5 [95% CI, 70.1 to 74.9] versus 63.7 [95% CI, 61.4 to 66.0] yr). Linear regression and renal survival analyses revealed that the location of PKD2 mutations did not influence the age of onset of ESRD. However, patients with splice site mutations appeared to have milder renal disease compared with patients with other mutation types (P < 0.04 by log rank test; adjusted for the gender effect). Considerable renal disease variability was also found among affected individuals with the same PKD2 mutations. This variability can confound the determination of allelic effects and supports the notion that additional genetic and/or environmental factors may modulate the renal disease severity in ADPKD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707387     DOI: 10.1097/01.asn.0000061774.90975.25

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  36 in total

1.  Molecular diagnostics in autosomal dominant polycystic kidney disease: utility and limitations.

Authors:  Xiao Zhao; Andrew D Paterson; Alireza Zahirieh; Ning He; Kairong Wang; York Pei
Journal:  Clin J Am Soc Nephrol       Date:  2007-12-12       Impact factor: 8.237

Review 2.  Molecular pathways and therapies in autosomal-dominant polycystic kidney disease.

Authors:  Takamitsu Saigusa; P Darwin Bell
Journal:  Physiology (Bethesda)       Date:  2015-05

Review 3.  Molecular diagnostics for autosomal dominant polycystic kidney disease.

Authors:  Peter C Harris; Sandro Rossetti
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

Review 4.  Determinants of renal disease variability in ADPKD.

Authors:  Peter C Harris; Sandro Rossetti
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

5.  A missense mutation in PKD1 attenuates the severity of renal disease.

Authors:  York Pei; Zheng Lan; Kairong Wang; Miguel Garcia-Gonzalez; Ning He; Elizabeth Dicks; Patrick Parfrey; Gregory Germino; Terry Watnick
Journal:  Kidney Int       Date:  2011-10-26       Impact factor: 10.612

Review 6.  Diagnosis, pathogenesis, and treatment prospects in cystic kidney disease.

Authors:  Carsten Bergmann; Valeska Frank; Fabian Küpper; Dirk Kamitz; Jens Hanten; Peter Berges; Silke Mager; Markus Moser; Jutta Kirfel; Reinhard Büttner; Jan Senderek; Klaus Zerres
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 7.  Predictors of autosomal dominant polycystic kidney disease progression.

Authors:  Robert W Schrier; Godela Brosnahan; Melissa A Cadnapaphornchai; Michel Chonchol; Keith Friend; Berenice Gitomer; Sandro Rossetti
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

Review 8.  Renal transplantation in autosomal dominant polycystic kidney disease.

Authors:  Nada Kanaan; Olivier Devuyst; Yves Pirson
Journal:  Nat Rev Nephrol       Date:  2014-06-17       Impact factor: 28.314

9.  Family history of renal disease severity predicts the mutated gene in ADPKD.

Authors:  Moumita Barua; Onur Cil; Andrew D Paterson; Kairon Wang; Ning He; Elizabeth Dicks; Patrick Parfrey; York Pei
Journal:  J Am Soc Nephrol       Date:  2009-05-14       Impact factor: 10.121

10.  Vasopressin directly regulates cyst growth in polycystic kidney disease.

Authors:  Xiaofang Wang; Yanhong Wu; Christopher J Ward; Peter C Harris; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2007-11-21       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.